TABLE 5.
Geometric mean (%CV) steady-state exposures for ceftazidime and avibactam and joint PTA at an MIC of 8 mg/liter summarized by indication (n = 5,000 simulated patients per cohort)a
| Cohort | Ceftazidime |
Avibactam |
Joint PTA, % | ||
|---|---|---|---|---|---|
| Cmax,ss (mg/liter) | AUCss,0–24 (mg ⋅ h/liter) | Cmax,ss (mg/liter) | AUCss,0–24 (mg ⋅ h/liter) | ||
| cIAI | 61.1 (44) | 683 (45) | 11.5 (83) | 121 (72) | 94.9 |
| cUTI | 73.0 (47) | 880 (49) | 11.2 (87) | 126 (82) | 95.2 |
| NP | 65.4 (53) | 805 (55) | 12.8 (94) | 147 (89) | 98.3 |
| VAP | 55.1 (59) | 719 (64) | 10.7 (85) | 129 (79) | 96.1 |
| Non-VAP | 75.7 (43) | 894 (48) | 14.7 (92) | 164 (93) | 100 |
This table adapted from Li et al. (16). The final population PK models included PK data from 1,975 subjects for ceftazidime and 2,249 subjects for avibactam. Simulations were conducted for 5,000 patients with normal renal function (CLCR >80 ml/min) for each indication, receiving ceftazidime-avibactam 2,000 + 500 mg, q8h, as a 2-h infusion (16). AUC and Cmax values are based on total plasma concentrations for ceftazidime and avibactam. AUCss,0–24, area under the curve over 24 h at steady state; cIAI, complicated intra-abdominal infection; Cmax,ss, maximum concentration at steady state; CLCR, creatinine clearance; cUTI, complicated urinary tract infection; CV, coefficient of variation; NP, nosocomial pneumonia; PK, pharmacokinetic; PTA; probability of target attainment; q8h, every 8 h; VAP, ventilator-associated pneumonia.